MedTrace Logo

CelluJuve® for the Treatment of Moderate to Severe NLFs

NCT07545980 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-22

No results posted yet for this study

Summary

Single-center, open-label proof of concept study assessing the safety and effectiveness of CelluJuve® for the treatment of moderate to severe NLFs

Conditions

  • Nasolabial Fold Wrinkles

Interventions

DEVICE

CelluJuve®

CelluJuve®

Sponsors & Collaborators

  • Spiderwort Biotechnologies Inc.

    lead INDUSTRY

Principal Investigators

  • Charles M Cuerrier, PhD · Spiderwort Biotechnologies Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-29
Primary Completion
2026-10-15
Completion
2028-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07545980 on ClinicalTrials.gov